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Abstract 13 
Biodeterioration of concrete by microorganism colonisation may be a problem in several 14 
structures, especially in irrigation and hydroelectric canals. The main problem in such 15 
structures is the proliferation of algae and cyanobacteria that affect the performance of the 16 
structure, increase the maintenance costs and affects its durability. A research was conducted 17 
to develop a novel cement-based material with biocide activity that can be used as an overlay 18 
mortar in existing structures, such as canals and pipes. With this aim, ten commercial biocides 19 
were evaluated in a laboratory campaign to assess the effectiveness of the compounds against 20 
the microbial colonization of concrete. Both mono- and multicomponent formulations were 21 
designed from the commercial products, to increase their antimicrobial effect obtaining a set 22 
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 2 
of biocide formulations. The formulations were submitted to a flowchart process to determine 23 
their influence on the physical properties of the concrete, evaluate the release of the actives, 24 
and their antimicrobial efficiency both before and after accelerated aging processes. During 25 
the campaign, some formulations were observed to diminish the strength of the concrete. 26 
Such behaviour was normally due to the interaction of the active with the cement hydration 27 
process. Other formulations showed a high release of active from the concrete in water, 28 
compromising the durability of the treatment. In general, monocomponent formulations did 29 
not succeed to fulfill all the requirements, thus multicomponent formulations were analysed. 30 
One studied multicomponent formulation presented particularly good results in all properties 31 
analysed. This product did not significantly change the properties of concrete and the release 32 
of active in water from the concrete was low, while the antimicrobial effects were long 33 
lasting. 34 
 35 
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 38 
1. Introduction 39 
Concrete is one of the most used construction materials because it has high structural 40 
performance, long durability, and a relatively low cost. The surface of concrete is resistant to 41 
corrosion and provides a physically and chemically stable environment that can be exposed to 42 
potable water or wastewater; for this reason, it is commonly used in pipes and canals (Alum et 43 
al., 2008). In these structures, microorganisms can easily colonise concrete and cause 44 
biodeterioration of the material. The main problem in irrigation and hydroelectric canals is the 45 
growth of algae and cyanobacteria among other microorganisms on the canal walls. This 46 
biological growth creates many problems that are reflected in increased maintenance costs. 47 
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 3 
The effective section of the canal is decreased and the roughness coefficient of the canal wall 48 
is increased, which diminishes the water flow (Lancar and Krake, 2002). Some studies reflect 49 
a decrease of 10% in the hydroelectric generation capacity because of algal growth 50 
(Andrewartha et al., 2007; Perkins et al., 2009). Furthermore, it is worth noting that presence 51 
of some types of fungi can have detrimental effects in concrete walls as well as can affect 52 
production of certain cereals, as Fusarium (Giannantonio at al., 2009). Moreover, the 53 
detachment of filamentous organisms such as green algae carries the risk of clogging and 54 
plugging filters. Both the growth of these organisms on concrete and the required cleaning 55 
activities to remove them from the walls cause erosion to the surface of the concrete. This 56 
intensifies the porosity and roughness of the material and makes it more vulnerable to re-57 
colonisation.  58 
 59 
Algal growth is usually preceded by concrete biofouling. This phenomenon is often grouped 60 
in the literature into several stages that include an initial accumulation of adsorbed organics, 61 
the settlement and growth of pioneering bacteria creating a biofilm matrix and the subsequent 62 
succession of micro and macrofoulers (Chambers et al., 2006). Usually, bacteria play a 63 
dominant role in the formation of this biofilm and further colonisation of larger 64 
microorganisms (Wei et al., 2013). 65 
 66 
Several antimicrobial treatments have been used in concrete and cement-based materials. 67 
Conventional studied procedures involve the usage of water repellents, biocides, or both. 68 
Water repellents slow the adsorption of water by reducing the surface energy and capillary 69 
forces of the concrete, thus decreasing the bioreceptivity of the material. Biocides focus on 70 
decreasing biological activity. While the use of hydrophobic compounds alone was shown to 71 
be insufficient in inhibiting microbial growth, the application of a combination of both 72 
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 4 
treatments has been reported as effective (Urzì and De Leo, 2007; De Muynck et al., 2009). 73 
The order of application of the different products influences the efficiency of the final 74 
treatment; this must be considered to avoid negative effects (Malagodi et al., 2000; Nugari 75 
and Salvadori, 2003; Moreau et al., 2008).  76 
 77 
Biocide treatments have one of two mechanisms: the elimination of the microorganisms 78 
already present on the material, and the prevention and control of microbial re-colonisation on 79 
clean surfaces. Many compounds have been analysed and tested over the years, including 80 
zeolites supporting heavy metal ions (such as copper and silver), zinc oxide, silver 81 
nanoparticles, pyridine biocides, silver nitrate, and quaternary ammonium compounds, or 82 
Quats (Urzì and De Leo, 2007; Alum et al., 2008; De Muynck et al., 2009; Eyssautier-Chuine 83 
et al., 2015). Quats are most frequently used because they have good efficacy as algaecides 84 
(Nugari et al., 2009). Nevertheless, this issue is far from being solved from a scientifically 85 
and technically point of view.  86 
 87 
The main aim of this paper is to present the results obtained in a research devoted to the 88 
development of cement-based materials with biocide activity to be used as a biocide mortar 89 
layout in existing concrete structures (Vaquero, 2013; Aguado et al., 2014). Therefore, 90 
different commercially available antimicrobial products were evaluated for effectiveness 91 
against microbial colonisation in concrete. These products were chosen for cost-effectiveness, 92 
non-toxicity, and capacity as disinfectants in other applications, such as floor and wall 93 
coverings. Different combinations of the commercial biocides were considered to increase 94 
their antimicrobial effect obtaining a set of biocide formulations. The experimental campaign 95 
was designed to evaluate the influence of the incorporation of the biocide formulations in 96 
concrete properties and their antimicrobial activity. Furthermore, the durability of the biocide 97 
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activity was also evaluated through accelerated aging processes. The performances of the 98 
different combinations studied are shown and analysed, with special attention to the reasons 99 
responsible for the failure of the formulations. 100 
 101 
2. Materials and methods 102 
2.1 Concrete specimens 103 
Concrete specimens were fabricated with the dosage shown in Table 1. The cement selected 104 
to produce the different mixtures was a CEM II A/V 42.5R. All aggregates were siliceous 105 
with a low fraction of particles under 0.125 mm sieve. The largest aggregate size was selected 106 
according to the size of the Petri dishes utilized for the microbiological tests. Furthermore, a 107 
large water-to-cement (w/c) ratio of the mixes (0.7) was used to obtain samples with high 108 
porosities that favoured microbiological colonisation. Lastly, a plasticiser additive (Pozzolith 109 
475N, BASF Construction Chemicals) was added to each mixture based on percentage over 110 
cement weight (% ocw). All concrete samples were made according to EN 12390-2 (AENOR, 111 
2009a). The samples were cured in a curing chamber (20° ± 2°C; 95 ± 5% relative humidity) 112 
for 28 days. 113 
 114 
Table 1. Concrete dosages for reference and biocide mixtures 115 
Compound Dosage (kg/m
3
) 
Cement 350
 
Fine aggregate (0-5 mm) 1074 
Coarse aggregate (5-12 mm)  724 
Plasticiser 3.5 (1%) 
Water 244 
 116 
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2.2 Design of biocide formulations 117 
Ten commercially available antimicrobial products (Table 2) were tested during the 118 
experimental campaign. These products were chosen for cost-effectiveness, non-toxicity, and 119 
capacity as disinfectants in other applications, such as floor and wall coverings. The 120 
antimicrobial products shown in Table 2 were used to develop different formulations for 121 
cement-based biocides. These biocide formulations were composed of one (monocomponent) 122 
or several antimicrobial products (multicomponent) as well as incorporating different 123 
additives in some cases (see Table 3). Multicomponent formulations were designed to achieve 124 
as wide a spectrum of antimicrobial action as possible. The content of each component of the 125 
formulations is given between brackets, expressed as percentage of the formulation. 126 
 127 
Table 2. General information on the different antimicrobial products evaluated 128 
Number Active  
Commercial 
name 
Effect 
Physical 
state 
1 
bis(2-pyridylthio)zinc 1,1'-
dioxide (Zinc pyrithione 10%) 
ACTICIDE SR 
1288® 
Fungicide and 
bactericide 
Liquid 
2 
1,2,3,6-Tetrahydro-N-
(trichloromethylthio)phthalimide 
BIOPOL D 212® Fungicide Powder 
3 
Dithio-2,2'-
bis(benzmethylamide) 
DENSIL P® 
Fungicide and 
bactericide 
Liquid 
4 
2-pyridinethiol-1-NaO + 1, 2-
benzisothiazole-3 (2H) -one 
P 24-81 
Fungicide and 
bactericide 
Powder 
5 
bis(2-pyridylthio)zinc 1,1'-
dioxide (Zinc pyrithione 10%) 
BC 98-56 
Fungicide and 
bactericide 
Powder 
6 
n-Butyl-1,2-benzisothiazolin-3-
one 
VANQUISH 100® 
Fungicide, 
bactericide 
and 
algaecide 
Liquid 
7 
Poly(hexamethylene biguanide) 
hydrochloride 
VANTOCIL IB® Bactericide Liquid 
8 
2-octyl-2H-isothiazol-3-one + 
Terbutryn 
ACTICIDE SR 
1453® 
Algaecide and 
fungicide 
Powder 
9 
n-Tert-butyl-N-cyclopropyl-6- 
(methylthio)-1,3,5-triazine-2,4-
diamine + 2 Octyl-2H-
isothiazol-3-one 
ACTICIDE MBP® 
Bactericide 
and fungicide 
Powder 
10 
2,4,4'-trichloro-2'-hydroxy-
diphenyl ether 
IRGASAN DP 
300® 
Bactericide 
and fungicide 
Powder 
 129 
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 130 
Table 3. General information on the biocide formulations 131 
Formulation name Active number Additives 
M
o
n
o
co
m
p
o
n
en
t 
BXT 1 Calcium filler (20%) 
BIOPOL D212 2 - 
DENSIL P 3 - 
P24-81 4 - 
BC 98-56 5 - 
VANQUISH 100 6 - 
VANTOCIL IB 7 - 
ACTICIDE MBP 9 - 
BXT/11 10 PG
 
(59.7%), TIBP
 
(0.3%), water (15%) 
BXT/AB 10 PG
 
(74.44%), TIBP
 
(0.45%), BUBLEX® (0.11) 
M
u
lt
ic
o
m
p
o
n
en
t BXT/1 1 (16%), 8 (59%) MOUSSEX® (4%), water (21%) 
BXT/5 1 (8%), 10 (3.45%) 
PG (10%), PEG (10%), TIBP (0.15%), 
OPTIGEL CR® (1.5%) 
BXT/10P 9 (15%), 10 (4%) MOUSSEX® (0.3%), Calcium filler (80.7) 
BXT/12C 1 (5.12%), 10 (5%) 
PG (12.23%), PEG
 
(77.34%), TIBP (0.21%), 
BUBLEX® (0.1%) 
PL-UV-H-2B 8 (30%), 10 (15%) MOUSSEX® (4%), Calcium filler (51%) 
 132 
As Table 3 shows, some additives were incorporated to improve the physical properties of the 133 
mixture. MOUSSEX®, BUBLEX®, and tri-isobutyl phosphate (TIBP) are used as defoamer 134 
compounds to avoid air entrapment in the concrete mix; propylene and polyethylene glycol 135 
(PG and PEG, respectively) are used as solvents instead of water to allow the solubilisation of 136 
the antimicrobial products and the collection of liquid admixtures; OPTIGEL CR® is an 137 
activated bentonite product used for anti-settling and stabilizing in water-based systems. 138 
Finally, calcium filler is used as a dispersive matrix for the biostatic agents. The biocide 139 
formulations were incorporated in the concrete mix in different amounts, as listed in Table 4; 140 
the dosage is expressed as percentage over dry weight of the mix (% odw). Concrete 141 
specimens were fabricated for each formulation dosage. Furthermore, reference samples were 142 
made for each biocide formulation without since cement samples may vary over time. These 143 
quantities were chosen based on the recommendations of the manufacturers of the products. 144 
Table 4 also provides information of the content of active principle in the formulations; in 145 
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 8 
case of multicomponent formulations, individual and total contents are given for each 146 
antimicrobial product. 147 
 148 
Table 4. Dosage of the biocide formulations and active contents 149 
Formulation name Dosage (% odw) 
Active content (kg/m3) 
A  B Total 
M
o
n
o
co
m
p
o
n
en
t 
BXT 
0.05 0.859 - 0.859 
0.15 2.578 - 2.578 
BIOPOL D212 
0.1 2.148 - 2.148 
0.2 4.296 - 4.296 
0.3 6.444 - 6.444 
DENSIL P 
0.2 4.296 - 4.296 
0.5 10.740 - 10.740 
1 21.480 - 21.480 
2 42.960 - 42.960 
P24-81 0.3 6.444 - 6.444 
BC 98-56 0.3 6.444 - 6.444 
VANQUISH 100 
0.002 0.043 - 0.043 
0.013 0.279 - 0.279 
0.025 0.537 - 0.537 
0.037 0.795 - 0.795 
0.05 1.074 - 1.074 
VANTOCIL IB 
0.3 6.444 - 6.444 
0.6 12.888 - 12.888 
1 21.480 - 21.480 
ACTICIDE MBP 
0.1 2.148 - 2.148 
0.4 8.592 - 8.592 
0.8 17.184 - 17.184 
BXT/11 
0.15 0.806 - 0.806 
0.18 0.967 - 0.967 
0.2 1.074 - 1.074 
0.22 1.181 - 1.181 
BXT/AB 
0.01 0.054 - 0.054 
0.05 0.269 - 0.269 
0.1 0.537 - 0.537 
0.15 0.806 - 0.806 
M
u
lt
ic
o
m
p
o
n
en
t 
BXT/1 
2.5 8.592 31.683 40.275 
3 10.310 38.020 48.330 
3.5 12.029 44.356 56.385 
BXT/5 
0.075 0.056 0.129 0.184 
0.15 0.111 0.258 0.369 
0.2 0.148 0.344 0.492 
0.4 0.296 0.687 0.984 
BXT/10P 
0.8 0.687 2.578 3.265 
1 0.859 3.222 4.081 
BXT/12C 
0.1 0.110 0.107 0.217 
0.6 0.660 0.644 1.304 
PL-UV-H-2B 
0.15 0.483 0.967 1.450 
0.2 0.644 1.289 1.933 
0.3 0.967 1.933 2.900 
 150 
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2.3 Experimental campaign 151 
The experimental campaign was designed as a flowchart, as described in Figure 1 with three 152 
consecutive main phases. Firstly, the influence of the different biocide formulations on 153 
physical properties of concrete was determined. Secondly, those biocide concretes that passed 154 
the first phase were subjected to a release test to determine the amount of active released from 155 
the sample. Finally, microbiological tests were conducted in those samples that passed the 156 
previous phases. The evaluation of antimicrobial properties was conducted twice, before and 157 
after an accelerated aging test, to simulate adverse conditions and thus estimate the durability 158 
of the tested treatment.  159 
 160 
Figure 1. Flowchart of the experimental campaign 161 
 162 
2.3.1 Physical characterisation of concrete specimens 163 
Concrete specimens were characterised to determine the influence of the biostatic 164 
formulations on the physical properties of the samples. Several parameters were considered in 165 
both the fresh and hardened state. Workability and density were characterised in the fresh 166 
concrete. The workability of the mixes was determined according to the ISO 1920-2 standard 167 
(ISO, 2005). The characterisation of the hardened concrete samples included density and 168 
mechanical properties determinations (compressive and flexural strength). The compressive 169 
and flexural strength measurements were made following EN 12390-4 and 5, respectively 170 
(AENOR, 2009b; c). 171 
 172 
2.3.2 Release of active 173 
Following the physical characterization of the concrete samples, release tests were performed 174 
to determine the amount of the active released from the samples. The method described in 175 
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prEN 16105:2010 (AENOR, 2010) is usually applied to evaluate leaching of substances from 176 
coatings and paints. Thus, it was selected to evaluate the release of active from the concrete 177 
samples, as the cement-based biocide developed is intended to be used as an overlay mortar 178 
for existing structures. This method subjects the samples to wetting-drying cycles to simulate 179 
the effects of rain and environmental conditions. After the wetting-drying cycles, the water 180 
samples are analysed to determine the amount of active released from the samples. 181 
 182 
Samples for the release tests were obtained from the same concrete dosages described 183 
previously. All samples presented at least 100 cm
2
 of surface area and with weights 184 
characterised both before and after the tests. For each analysis, duplicate samples of each 185 
biocide mixture were studied. Furthermore, one reference sample was also analysed. All 186 
samples were maintained for 7 days at 23° ± 2° C at a relative humidity of 50 ± 5%. The 187 
subsequent immersion process lasted 24 days. During that time, nine wetting-drying cycles 188 
were performed on days 1, 3, 7, 9, 14, 16, 18, 22, and 24. Each cycle contained the following 189 
steps: 1 h immersion, 4 h drying, 1 h immersion, and 48 h drying. At the end of the cycle, the 190 
water samples were collected and analysed by HPLC analyses and pH measurements.  191 
 192 
The amount of active present in the solution after the release tests can be expressed according 193 
to Eq. (1). Here, M is the amount of active expressed in mg/m
2
·day, c is the measured 194 
concentration of active in the eluate in mg/L, Vreal is the real volume of eluate after each 195 
immersion day in L, A is the effective surface area exposed to the releasing test in m
2
, and t is 196 
the day of immersion. 197 
 



realc VM
A t
  (1) 198 
 199 
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2.3.3 Evaluation of antimicrobial properties 200 
The different concrete samples were tested to determine their antimicrobial properties both 201 
before and after accelerated aging processes to estimate the durability of the treatments. 202 
Several samples from the different concrete mixes were exposed to suspensions containing 203 
different microorganisms. The characteristics of the microorganisms used are described in 204 
Table 5. The microorganisms were collected from different culture media from the American 205 
Type Culture Collection (ATCC) and the Sammlung von Algenkulturen Göttingen (SAG). 206 
 207 
Table 5. Microorganisms used for to evaluate antimicrobial properties and characteristics of 208 
incubation periods thereof 209 
Type of 
microorganism 
Microorganism 
Reference 
code 
Incubation period 
Agar type 
Temperature 
(°C) 
Time 
(days) 
Fungus 
Aspergillus 
niger 
ATCC 6275 
Malt extract 
agar 
25 ± 2 5-7 
Bacteria 
Staphylococcus 
aureus 
ATCC 6538P Nutrient 
agar 
30 ± 2 2 
Bacteria Escherichia coli ATCC 8739 30 ± 2 2 
Algae 
Scenedesmus 
vaculatus 
SAG 211-8b 
Kuhl 
solution 
20 ± 2 21 
Algae 
Stichococcus 
bacillaris 
SAG 379-1a 20 ± 2 21 
 210 
The concrete samples were located in Petri dishes containing agar media specialized for each 211 
microorganism. The concrete samples were of 10 mm thickness and variable sizes, obtained 212 
from the samples described in section 2.3. The different microorganism suspensions were 213 
spread over the agar surface. Each suspension contained at least 5 × 10
6
 organisms per mL. 214 
The Petri dishes with the concrete samples and the suspensions were incubated as detailed in 215 
Table 5. At the end of the incubation period, the antimicrobial properties of the samples were 216 
evaluated. The samples were visually analysed to determine the growth of the 217 
microorganisms and classified by the following scale: 0 – no visible growth of 218 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 12 
microorganisms; 1 – slight observable growth of microorganisms; 2 – evident growth of 219 
microorganisms and presence of spores. 220 
 221 
As mentioned above, after the first evaluation of the antimicrobial properties an accelerated 222 
aging process was conducted to simulate the adverse conditions concrete can experience, thus 223 
evaluating antimicrobial efficiency over time. The exposure test Xenotest 150S was 224 
performed. This test was designed to evaluate the durability of paints and varnishes, and 225 
consists of an uninterrupted irradiation of the samples for 2000 h with 340 nm radiation at a 226 
radiant flux of 0.5 W/m
2
, in UNE-EN ISO 4892-2 (AENOR, 2014) standard conditions. This 227 
treatment is equivalent to 6-8 months of continuous strong sunlight. By using ultraviolet 228 
fluorescent lamps and irrigation sprinklers, the process simulates environmental wear accrued 229 
over a much longer period than actually experienced. The samples exposed to the accelerated 230 
aging process and others with the same characteristics without aging were evaluated a second 231 
time with respect to antimicrobial properties, and the differences in the capacity of the 232 
samples to inhibit microbial growth were compared and examined.  233 
 234 
3. Results and discussion 235 
3.1 General evaluation 236 
During the experimental campaign, the biocide formulations shown in Table 3 were submitted 237 
to the flowchart process described in section 2.2. Those that did not present good results in a 238 
given phase were immediately discarded from the experiment to save time and cost. At first, 239 
only monocomponent formulations were evaluated. None of them was able to pass the whole 240 
evaluation process, as shown in Table 6. Some of the formulations failed in the physical 241 
properties evaluation phase (BXT/AB, BXT/11, VANQUISH 100, DENSIL P and BC 98-56); 242 
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formulations BIOPOL D212 and VANTOCIL IB did not passed releasing tests; finally, 243 
ACTICIDE MBP, P24-82 and BXT were discarded after the antimicrobial test.  244 
 245 
Considering these results, multicomponent formulations were tested to increase the 246 
antimicrobial activity and/or to overcome the problems observed during the first evaluation 247 
phase. Five multicomponent formulations were designed and analysed. Only one of the 248 
multicomponent formulations (PL-UV-H-2B) presented good results during the complete 249 
evaluation process. Table 6 presents a summary of the phase at which the formulation was 250 
discarded. 251 
 252 
Table 6. Failure phases and qualification of each formulation during the experimental 253 
campaign 254 
Formulation Failure phase 
M
o
n
o
co
m
p
o
n
en
t 
BXT/AB Physical properties 
BXT/11 Physical properties 
ACTICIDE MBP Antimicrobial properties (before aging process) 
BIOPOL D212 Releasing test 
VANTOCIL IB Releasing test 
VANQUISH 100 Physical properties 
DENSIL P Physical properties 
P24-81 Antimicrobial properties (before aging process) 
BC 98-56 Physical properties 
BXT Antimicrobial properties (after aging process) 
M
u
lt
ic
o
m
p
o
n
en
t BXT/12C Physical properties 
BXT/10P Physical properties 
BXT/1 Physical properties 
BXT/5 Antimicrobial properties (before aging process) 
PL-UV-H-2B None 
 255 
 256 
 257 
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3.2 Physical characterisation  258 
Firstly, the results obtained by the monocomponent formulations will be analysed. Five out of 259 
ten of the monocomponent formulations affected the physical properties of the concrete 260 
samples, mainly with respect to strength.  Only the results of these formulations will be 261 
analysed here. The results of mechanical performance of these samples are shown in Table 7, 262 
along with the measurements of workability and density in fresh state.  263 
 264 
Table 7. Mechanical properties of the monocomponent formulations failing first phase tests 265 
Formulation 
name 
Dosage 
(% 
odw) 
Flow 
(mm) 
Fresh 
density 
(kg/m
3
) 
Mechanical properties (MPa) 
Compressive 
strength 
Flexural 
strength 
1 d 28d 1d 28d 
DENSIL P 
0 154 2450 19.1 47.8 4.8 8.2 
0.2 154 2435 19.3 48.3 4.6 9.4 
0.5 155 2435 8.5 41.1 2.2 7.2 
1.0 155 2435 4.4 42.1 1.2 8.3 
2.0 159 2422 n.d. 34.2 n.d. 7.3 
BC 98-56 
0 150 2432 12.8 33.5 3.5 6.8 
0.3 135 2465 n.d. 36.6 n.d. 7.6 
VANQUISH 100 
0 155 2450 15.4 33.6 3.3 6.5 
0.002 152 2392 14.2 33.1 2.9 6.1 
0.013 152 2401 13.1 29.2 2.8 5.6 
0.025 153 2417 13.4 27.4 3.0 5.5 
0.037 156 2439 12.8 30.9 3.0 5.4 
0.050 150 2427 12.8 27.4 2.5 5.8 
BXT/11 
0 117 2389 15.5 35.1 3.2 5.6 
0.15 118 2005 5.3 16.0 2.1 3.3 
0.18 122 2004 7.2 21.4 2.5 5.2 
0.20 121 2122 6.9 20.9 2.7 5.3 
0.22 127 2174 9.6 24.3 2.4 5.8 
BXT/AB 
0 117 2389 15.5 35.1 3.2 5.6 
0.01 120 2420 15.1 29.9 2.6 5.4 
0.05 125 2395 14.8 34.3 2.8 5.4 
0.10 128 2467 13.0 31.8 2.3 5.0 
0.15 124 2397 11.9 29.8 2.1 4.9 
 266 
The results shown in Table 7 direct evidence the biocide formulations affected the concrete 267 
samples in two different ways. The first phenomenon observed was the influence of the active 268 
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principles in the cement hydration process. Most of the formulations exhibited this 269 
phenomenon.  The formulations BXT/AB, VANQUISH 100 and DENSIL P mainly 270 
influenced early-age properties of the concrete samples. Concrete samples made with these 271 
formulations presented results similar to those from the reference concrete regarding 272 
workability and density, with variations lower than 5% in these properties. However, the 273 
mechanical resistances decreased significantly, especially at lower ages. The reduction of 274 
compressive strength increases with increased biocide formulation dosages, e.g.: concrete 275 
samples made with BXT/AB formulation reached a 23% reduction of compressive strength 276 
with a dose of 0.15% at 1 day, and a 35% reduction of flexural strength at the same dose and 277 
age. In this case, the active principles are retarding the cement hydration process thus 278 
reducing compressive and flexural strengths in relation to the reference samples. The 279 
strengths obtained at 28 days showed slight recovery, although they remained below the 280 
reference value. 281 
 282 
BC 98-56 formulation also influenced the cement hydration process but in a different way. 283 
This formulation modified the workability of the concrete samples by increasing the viscosity 284 
of the fresh mix. A strong diminution of the resistances at 24 h was observed and the samples 285 
could not be demoulded. Mechanical properties at 28 days were higher than those of the 286 
reference concrete were. This behaviour could be explained by the influence of the active 287 
principle on the cement hydration process, generating smaller but more proliferate crystals. 288 
Consequently, the crystallization process would be slower and the resistances would increase 289 
with age.  290 
 291 
The second phenomenon observed was air-entrapment, evidenced in concrete samples made 292 
with BXT/11 formulation. This formulation was designed with the same active principle as 293 
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BXT/AB, but with a reduced amount of propylene glycol and water substituted to improve the 294 
stability of the solution. With this reduction, the amount of defoamer compound was also 295 
decreased; only TIBP was used. In these samples, significant reductions were observed in 296 
their densities. The addition of IRGASAN DP 300® produced air entrapment in the concrete 297 
mix and diminished the density, thus requiring increased amounts of defoamer to release 298 
entrapped air. Another important aspect was observed regarding to the densities of the 299 
antimicrobial samples. The increased amount of biostatic agent in the mix did not produce a 300 
proportional reduction of the densities, but quite the opposite; as the content of biocide 301 
increased, the density also increased. This phenomenon may result from the increased amount 302 
of biostatic agent being accompanied by an increased amount of defoamer compounds in the 303 
concrete, thus reducing air entrapment. The influence of the formulation on the densities of 304 
the mixtures produced significant reductions in the strength values, with a maximum 305 
diminution of 66% in compressive strength with a dose of 0.15% at 1 day. 306 
 307 
Regarding the multicomponent formulations evaluated, most of them did not present good 308 
results during the evaluation of their mechanical performance. This was the case for BXT/1, 309 
BXT/10P, and BXT/12C; the compressive and flexural strengths of these compounds are 310 
shown in Table 8, as well as the workability and density measurements in fresh state. A trend 311 
in both compressive and flexural strengths of the concrete samples is observed; the decreases 312 
in strength are directly proportional to the increases of biocide contents in the mixtures. The 313 
controlling factor in this decrease of strength is again the influence of the active principles in 314 
the cement hydration process. Minor influences are observed in workability and density in 315 
fresh state of the concrete samples as compared with the reference samples. Nevertheless, 316 
large reductions in compressive strength are observed for the samples containing BXT/1, 317 
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BXT/10P, and BXT/12C formulations. Furthermore, samples with BXT/1 formulation could 318 
not be demoulded at the age of 24 hours. 319 
 320 
Table 8. Mechanical properties of the multicomponent formulations 321 
Formulation 
name 
Dosage 
(% 
odw) 
Flow 
(mm) 
Fresh 
density 
(kg/m
3
) 
Mechanical properties (MPa) 
Compressive 
strength 
Flexural 
strength 
1 d 28d 1d 28d 
BXT/1 
0 157 2426 12.5 36.7 3.7 7.5 
0.4 150 2465 n.d. 34.0 n.d. 6.7 
0.45 153 2439 n.d. 31.2 n.d. 6.5 
0.5 149 2468 n.d. 34.3 n.d. 6.3 
BXT/5 
0 165 2343 15.8 42.3 4.8 8.7 
0.08 170 2337 14.9 40.5 4.3 8.1 
0.15 167 2381 15.1 40.0 3.8 8.4 
0.2 165 2330 14.5 39.0 3.5 7.9 
0.4 168 2327 14.0 39.0 3.3 7.7 
BXT/10P 
0 125 2473 19.1 35.0 4.8 7.2 
0.8 117 2266 10.3 30.6 2.8 6.1 
1 120 2200 8.2 29.0 2.5 6.0 
BXT/12C 
0 117 2389 12.8 33.5 3.5 6.8 
0.6 120 2420 8.1 28.4 2.8 5.6 
1 125 2395 6.2 22.7 2.3 4.4 
PL-UV-H-2B 
0 148 2523 14.3 37.1 4.0 9.4 
0.15 152 2501 12.7 36.9 3.5 8.6 
0.2 145 2479 11.3 35.7 2.8 8.2 
0.3 150 2484 14.0 34.9 3.2 8.5 
 322 
Only BXT/12C and PL-UV-H-2B formulations did not significantly change the physical 323 
properties of the concrete mixtures. Both fresh and apparent densities are in the same range of 324 
values, with differences under 2%. Minor reductions in the fresh density of samples 325 
elaborated with the highest dosage of PL-UC-H-2B formulation are observed. This reduction 326 
is related with an air-entrapping process, since the formulation was designed as a solid 327 
powder because of the difficulties of obtaining a stable suspension of the antimicrobial 328 
products. Although minor variations of compressive and flexural strength are observed, these 329 
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are negligible and do not evidence shortcomings in the mechanical performances of the 330 
concretes. 331 
 332 
 333 
3.3 Release of active  334 
Releasing tests were made in those monocomponent formulations that succeeded the first 335 
phase of physical characterization (ACTICIDE MBP, BIOPOL D212, VANTOCIL IB, P24-336 
81, and BXT). The releasing curves of the actives from concrete samples containing each 337 
formulation are shown in Figure 2; in the case of P24-81 formulation, separated curves are 338 
shown for each active (NaP: 2-pyridinethiol-1-NaO; BIT: 1,2-benzisothiazole-3(2H)-one). 339 
For each formulation, daily and accumulated concentrations are given on the right and left 340 
side of the figure, respectively). According to the same procedure used in the physical 341 
characterization tests, the formulations that did not present good results in this phase were 342 
discarded, as occurred with the monocomponent formulations Biopol D212 and Vantocil IB 343 
(see Figure 2b and 2c). Although the releasing levels of Biopol D212 are far from toxicity, as 344 
the value considered detrimental for humans of this product is LD50 > 9000 ppm, this high 345 
solubility in water could quickly decrease the antimicrobial efficiency of the treated concrete. 346 
The formulation seemed excessively soluble for the intended purpose and thus it was 347 
discarded. Similar behaviour was observed with the formulation Vantocil IB in the releasing 348 
test. The amount of active released increases as the dosage of the antimicrobial mixture is 349 
increased, for both formulations. 350 
 351 
Figure 2. Releasing curves of the active from concrete fabricated with monocomponent 352 
formulations: a) ACTICIDE MBP, b) BIOPOL D212, c) VANTOCIL IB, d) P24-81, and e) 353 
BXT 354 
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 355 
Regarding the multicomponent formulations, releasing tests were made only in PL-UV-H-2B 356 
formulations since BXT/5 formulation is comparable to monocomponent formulations 357 
ACTICIDE MBP and BXT. The releasing curves of the active from concrete samples 358 
containing the formulation PL-UV-H-2B are shown in Figure 3; separated curves are 359 
provided for each active present in the formulation (OIT: 2-octyl-2H-isothiazol-3-one; TER: 360 
terbutryn). As expected, an increase in the actives released is observed with increasing 361 
dosages of the formulation. For the sample with 0.15% dosage of the formulation, the actives 362 
are mainly released during the first 9 days of the test. Afterwards, only minor releasing is 363 
observed. The sample with 0.2% dosage presents higher released quantities of actives 364 
throughout the releasing test. An anomalous measurement at 14 days is much higher for OIT 365 
than the rest (0.45 mg/m
2
). If this value is not considered, the total amount of active released 366 
from the sample is proportional to the initial content of the active in the concrete sample. 367 
 368 
Figure 3. Releasing curves of the active from concrete fabricated with PL-UV-H-2B 369 
formulation 370 
 371 
For the highest tested dosage of PL-UV-H-2B formulation (0.3%), the quantities of active 372 
released are much larger than the ones for the other dosages. The release of active from the 373 
sample during the first 7 days is approximately six times greater compared to the results of the 374 
0.15% sample, thus increasing until the end of the process. The total active released from the 375 
0.3% sample is more than nine times larger than that from the 0.15% sample. This behaviour 376 
suggests possible interactions between the active and the cementitious matrix. However, as 377 
the content of formulation is increased above 0.2%, there is more free active in the pore 378 
solution; hence, the active released increases during the duration of the test. The total amount 379 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 20 
of active released throughout the test is far below toxic values. The sample with the largest 380 
content of formulation releases a total amount of 1.52 mg/m
2
 of actives, which is equivalent 381 
to 0.3 ppm. This antimicrobial product is considered toxic for humans at LD50 > 2360 ppm, 382 
which is almost four orders of magnitude larger than the total amount of active released from 383 
the sample during the releasing test.  384 
 385 
3.4 Evaluation of the antimicrobial properties 386 
The final phase of the experimental campaign was only performed on those formulations that 387 
had presented good results in both previous phases, as described in sections 3.2 and 3.3. Three 388 
monocomponent formulations (ACTICIDE MBP, P 24-81, and BXT) were evaluated, but 389 
none presented good results after the process. Two multicomponent formulations (BXT/5 and 390 
PL-UV-H-2B) were also subjected to the microbiological test.  391 
 392 
Firstly, the results obtained by concrete samples fabricated with ACTICIDE MBP formulation 393 
will be presented. This monocomponent formulation was expected to have bactericide and 394 
fungicide activity. Therefore, it was tested against three microorganisms (Escherichia coli, 395 
Staphylococcus aureus, and Aspergillus niger). Figure 6 depicts images of the evaluation of 396 
the antimicrobial tests performed with this formulation. The concrete samples show good 397 
efficiency against Staphylococcus aureus, preventing biological growth on the surface with a 398 
growth index of 0 in all treated samples; the reference sample presents a growth index of 2. 399 
However, the concrete samples do not inhibit surface growth of Escherichia coli or 400 
Aspergillus niger, presenting a growth index of 2 at all dosages. Since the antimicrobial 401 
activity against two of the three microorganisms is negligible, the product is considered not 402 
valid. 403 
 404 
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Figure 4. Effectiveness of concrete made with Acticide MBP formulation against different 405 
microorganisms 406 
 407 
Secondly, concrete samples made with P 24-81 formulation were analysed; the results of the 408 
antimicrobial tests are shown in Figure 5. This formulation was also expected to present 409 
bactericide and fungicide activity; it was tested against the same microorganisms as samples 410 
made with ACTICIDE MBP formulation. The treated samples contained 0.3% odw. After the 411 
microbiological test, the compound presented no antimicrobial properties against any 412 
microorganism, with no inhibition of biological growth on the surface of the sample. The 413 
visual analysis (see Figure 5) showed a growth index of 2 in all cases; hence, it was also 414 
discarded before the accelerated aging process. 415 
 416 
Figure 5. Effectiveness of concrete made with P 24-81 formulation against different 417 
microorganisms 418 
 419 
Finally, BXT formulation was analysed. This product was expected to have biocide and 420 
fungicide activity. In initial antimicrobial tests, shown in Figure 6a, the product exhibits good 421 
antimicrobial properties against both types of bacteria, with a growth index of 0 in every case. 422 
Nevertheless, the effect against the Aspergillus niger fungus is only acceptable with the 423 
dosage of 0.15% with a growth index of 1; this index has a value of 2 for the sample with the 424 
lowest dose of 0.05%. The results are considered sufficient for validity, and the samples were 425 
submitted to the accelerated aging test. A second antimicrobial test was conducted following 426 
the same procedure. After aging, the inhibition of bacterial growth is retained, as seen in 427 
Figure 6b, with a growth index of 0 in all cases. However, the antimicrobial activity against 428 
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Aspergillus niger is not preserved, as the growth index reaches 2 with both dosages; thus, the 429 
product is considered not valid. 430 
 431 
 Figure 6. Effectiveness of concrete made with BXT formulation against different 432 
microorganisms: a) before and b) after the accelerated aging process 433 
 434 
Regarding the multicomponent formulations, BXT/5 formulation is composed of the active 435 
principles IRGASAN DP 300® and ACTICIDE SR 1288®, and it was tested against all 436 
microorganisms listed in Table 5 to evaluate its antimicrobial efficiency. After the biological 437 
tests, the treatment showed great efficiency against the bacteria Staphylococcus aureus and 438 
the two types of algae, Scenedesmus vaculatus and Stichococcus bacillaris, with growth 439 
indexes of 0 for all dosages, as seen in Figure 7. In these cases, no biological growth occurred 440 
on the surfaces, and inhibition halos surrounding the samples were observed. However, the 441 
formulation did not present antimicrobial activity against Escherichia coli at any dose. This 442 
may be due to the low content of ACTICIDE SR 1288® in the mixtures; BXT, which had the 443 
same active principle but in greater amounts, presented highly antimicrobial behaviour. The 444 
growth indexes against this microorganism with BXT/5 were 2 in all cases (see Figure 7). The 445 
treatment was also inefficient against the fungus Aspergillus niger, reaching only an 446 
acceptable level of activity, with a growth index of 1, at the highest dose (0.4%). At all other 447 
doses, the growth index was 2, with no inhibition of biological growth. The unsatisfactory 448 
behaviour of the treatment against Escherichia coli and Aspergillus niger justified the 449 
discarding of the treatment without accelerated aging. 450 
 451 
Figure 7. Effectiveness of concrete made with BXT/5 formulation against different 452 
microorganisms: a) before and b) after the accelerated aging process 453 
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 454 
Finally, concrete samples made with PL-UV-H-2B formulation were analysed. Figure 8a 455 
shows the results of microorganism colonisation after the incubation period of the 456 
formulation. As noted in section 3.1, because the formulation is expected to present algaecide, 457 
bactericide, and fungicide activity, the compound was tested against all microorganisms listed 458 
in Table 5 to evaluate its antimicrobial efficiency. The concrete samples present efficiency 459 
against all microorganisms evaluated at all dosages; it prevents biological growth on the 460 
surface and, in most cases, forms an inhibition halo surrounding the sample. With both 461 
bacteria and algae, the concrete shows high antimicrobial activity with growth indexes of 0 in 462 
all cases. With Aspergillus niger, higher formulation dosages of 0.2 and 0.3% are required to 463 
obtain the same effect, as the lowest dose of 0.1% presents a growth index of 1 with no 464 
inhibition halo surrounding the sample surface. The growth indexes for the reference samples 465 
against the different microorganisms vary from 1 to 2.  466 
 467 
Figure 8. Effectiveness of concrete made with PL-UV-H-2B formulation against different 468 
microorganisms: a) before and b) after the accelerated aging process 469 
 470 
According to the results of the initial antimicrobial test, the formulation PL-UV-H-2B was 471 
considered valid and the samples were then subjected to the accelerated aging test. A second 472 
antimicrobial test was conducted; images of the microbiological cultures are shown in Figure 473 
8b. The antimicrobial activities against both bacteria and algae prevail after the aging process, 474 
although larger inhibition halos surrounding the samples are observed at higher dosages of the 475 
formulation. The growth index in all cases is zero. For the efficiency against fungal growth, a 476 
slight loss of the antimicrobial activity is perceived because the inhibition halo is not formed 477 
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at any dosage. However, no biological growth occurs on the concrete samples; the growth 478 
index is 1 for the samples with different biocide doses. 479 
 480 
4. Conclusions 481 
Fifteen biocide formulations were studied during this campaign to assess their biocide effects 482 
when incorporated into concrete. These formulations were elaborated from different 483 
commercially available antimicrobial products that were chosen for cost-effectiveness, non-484 
toxicity, and capacity as disinfectants in other applications, such as floor and wall coverings. 485 
The biocide formulations were composed of one (monocomponent) or more antimicrobial 486 
products (multicomponent) as well as incorporating different additives in some cases. 487 
 488 
A three-phase process was performed to evaluate the physical properties, release of active and 489 
antimicrobial properties of the concrete samples incorporating the different formulations. The 490 
study showed that monocomponent formulations were insufficient to inhibit biological growth 491 
in concrete without either significant detriment to the mechanical properties of the material or 492 
losing efficient biostatic activity after a short period. To obtain a long-lasting effect against a 493 
wide spectrum of microorganisms, the use of multicomponent formulations was necessary.  494 
 495 
The use of existing commercial products such as Vanquish 100®, Densil P®, and BC 98-56 496 
presented significant reductions in the mechanical resistances of concrete, typically with 497 
influences during the hardening process. The formulations BXT/AB and BXT/11, which 498 
incorporated IRGASAN DP 300®, also showed decreases in the strengths of the concrete. 499 
This active principle, in certain compositions, caused a decrease in density through air 500 
entrapment in the concrete mix. Some multicomponent formulations, such as BXT/12C, 501 
BXT/10P, and BXT/1, also presented poor performance regarding mechanical properties. The 502 
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effect of the biostatic agents in the cement hydration process was the main reason for the 503 
mechanical degradation of the concrete, especially at low ages.  504 
 505 
Many of the formulations affected significantly the physical and mechanical properties of the 506 
concrete samples, thus presenting lower mechanical performances. Two different behaviour 507 
were observed. According to the results obtained, some formulations presented an interaction 508 
of the actives with the cement hydration process. The low mechanical performance of the 509 
samples at early ages may be related with the retardation of the hydration reactions. 510 
Furthermore, air-entrapping was also observed. The formulations Vanquish 100®, Densil P®, 511 
and BC 98-56, as well as BXT/AB and BXT/11, which incorporated IRGASAN DP 300®, 512 
were discarded from the evaluation process.  513 
 514 
The addition of the chemicals Biopol D212® and Vantocil IB® did not affect the strengths of 515 
the concrete mixtures. However, when submitted to release tests, the modified samples 516 
presented high solubility in water. This behaviour implied a rapid loss of antimicrobial 517 
activity, which would compromise the duration of protection. 518 
 519 
In the microbiological tests, the chemicals ACTICIDE MBP® and P 24-81 presented poor 520 
results with almost no inhibition of biological growth. BXT offered good results against both 521 
types of bacteria and the tested fungus before the accelerated aging process. However, after 522 
aging, the activity against the fungus was not maintained. The multicomponent formulation 523 
BXT/5 showed a high antimicrobial efficiency against both algae species and the bacteria 524 
Staphylococcus aureus. Despite these results, the treatment did not present any biocide effect 525 
against Escherichia coli and Aspergillus niger.  526 
 527 
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Among all the formulations evaluated, the formulation PL-UV-H-2B was the only one to 528 
succeed in all the evaluation process. This multicomponent formulation, when mixed with 529 
concrete, did not affect the physical or mechanical properties of the material. Only slight 530 
reductions in density, compressive strength, and flexural strength were observed in 531 
comparison with those of the reference samples, although the reductions were not significant.  532 
 533 
Concerning the release tests, the quantity of active released by this formulation was very low. 534 
The quantities released are approximately four orders of magnitude below the amount that 535 
may be considered toxic for humans. This result also indicates a greater duration of the 536 
biostatic effect of the treatment.  537 
 538 
Moreover, concrete samples fabricated with PL-UV-H-2B formulation demonstrated high 539 
effectiveness in antimicrobial tests against algae, fungi, and bacteria, both before and after 540 
accelerated aging processes. The compound prevented biological growth in concrete, and in 541 
most cases formed inhibition halos surrounding the samples. 542 
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Table 1. Concrete dosages for reference and biocide mixtures 
Compound Dosage (kg/m
3
) 
Cement 350
 
Fine aggregate (0-5 mm) 1074 
Coarse aggregate (5-12 mm)  724 
Plasticiser 3.5 (1%) 
Water 244 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table
Table 2. General information on the different antimicrobial products evaluated 
Number Active  
Commercial 
name 
Effect 
Physical 
state 
1 
bis(2-pyridylthio)zinc 1,1'-
dioxide (Zinc pyrithione 10%) 
ACTICIDE SR 
1288® 
Fungicide and 
bactericide 
Liquid 
2 
1,2,3,6-Tetrahydro-N-
(trichloromethylthio)phthalimide 
BIOPOL D 212® Fungicide Powder 
3 
Dithio-2,2'-
bis(benzmethylamide) 
DENSIL P® 
Fungicide and 
bactericide 
Liquid 
4 
2-pyridinethiol-1-NaO + 1, 2-
benzisothiazole-3 (2H) -one 
P 24-81 
Fungicide and 
bactericide 
Powder 
5 
bis(2-pyridylthio)zinc 1,1'-
dioxide (Zinc pyrithione 10%) 
BC 98-56 
Fungicide and 
bactericide 
Powder 
6 
n-Butyl-1,2-benzisothiazolin-3-
one 
VANQUISH 100® 
Fungicide, 
bactericide 
and 
algaecide 
Liquid 
7 
Poly(hexamethylene biguanide) 
hydrochloride 
VANTOCIL IB® Bactericide Liquid 
8 
2-octyl-2H-isothiazol-3-one + 
Terbutryn 
ACTICIDE SR 
1453® 
Algaecide and 
fungicide 
Powder 
9 
n-Tert-butyl-N-cyclopropyl-6- 
(methylthio)-1,3,5-triazine-2,4-
diamine + 2 Octyl-2H-
isothiazol-3-one 
ACTICIDE MBP® 
Bactericide 
and fungicide 
Powder 
10 
2,4,4'-trichloro-2'-hydroxy-
diphenyl ether 
IRGASAN DP 
300® 
Bactericide 
and fungicide 
Powder 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. General information on the biocide formulations 
Formulation name Active number Additives 
M
o
n
o
co
m
p
o
n
en
t 
BXT 1 Calcium filler (20%) 
BIOPOL D212 2 - 
DENSIL P 3 - 
P24-81 4 - 
BC 98-56 5 - 
VANQUISH 100 6 - 
VANTOCIL IB 7 - 
ACTICIDE MBP 9 - 
BXT/11 10 PG (59.7%), TIBP (0.3%), water (15%) 
BXT/AB 10 PG (74.44%), TIBP (0.45%), BUBLEX® (0.11) 
M
u
lt
ic
o
m
p
o
n
en
t BXT/1 1 (16%), 8 (59%) MOUSSEX® (4%), water (21%) 
BXT/5 1 (8%), 10 (3.45%) 
PG (10%), PEG (10%), TIBP (0.15%), 
OPTIGEL CR® (1.5%) 
BXT/10P 9 (15%), 10 (4%) MOUSSEX® (0.3%), Calcium filler (80.7) 
BXT/12C 1 (5.12%), 10 (5%) 
PG (12.23%), PEG
 
(77.34%), TIBP (0.21%), 
BUBLEX® (0.1%) 
PL-UV-H-2B 8 (30%), 10 (15%) MOUSSEX® (4%), Calcium filler (51%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Dosage of the biocide formulations and active contents 
Formulation name Dosage (% odw) 
Active content (kg/m3) 
A  B Total 
M
o
n
o
co
m
p
o
n
en
t 
BXT 
0.05 0.859 - 0.859 
0.15 2.578 - 2.578 
BIOPOL D212 
0.1 2.148 - 2.148 
0.2 4.296 - 4.296 
0.3 6.444 - 6.444 
DENSIL P 
0.2 4.296 - 4.296 
0.5 10.740 - 10.740 
1 21.480 - 21.480 
2 42.960 - 42.960 
P24-81 0.3 6.444 - 6.444 
BC 98-56 0.3 6.444 - 6.444 
VANQUISH 100 
0.002 0.043 - 0.043 
0.013 0.279 - 0.279 
0.025 0.537 - 0.537 
0.037 0.795 - 0.795 
0.05 1.074 - 1.074 
VANTOCIL IB 
0.3 6.444 - 6.444 
0.6 12.888 - 12.888 
1 21.480 - 21.480 
ACTICIDE MBP 
0.1 2.148 - 2.148 
0.4 8.592 - 8.592 
0.8 17.184 - 17.184 
BXT/11 
0.15 0.806 - 0.806 
0.18 0.967 - 0.967 
0.2 1.074 - 1.074 
0.22 1.181 - 1.181 
BXT/AB 
0.01 0.054 - 0.054 
0.05 0.269 - 0.269 
0.1 0.537 - 0.537 
0.15 0.806 - 0.806 
M
u
lt
ic
o
m
p
o
n
en
t 
BXT/1 
2.5 8.592 31.683 40.275 
3 10.310 38.020 48.330 
3.5 12.029 44.356 56.385 
BXT/5 
0.075 0.056 0.129 0.184 
0.15 0.111 0.258 0.369 
0.2 0.148 0.344 0.492 
0.4 0.296 0.687 0.984 
BXT/10P 
0.8 0.687 2.578 3.265 
1 0.859 3.222 4.081 
BXT/12C 
0.1 0.110 0.107 0.217 
0.6 0.660 0.644 1.304 
PL-UV-H-2B 
0.15 0.483 0.967 1.450 
0.2 0.644 1.289 1.933 
0.3 0.967 1.933 2.900 
 
 
 
 
 
 
 
Table 5. Microorganisms used for to evaluate antimicrobial properties and 
characteristics of incubation periods thereof 
Type of 
microorganism 
Microorganism 
Reference 
code 
Incubation period 
Agar type 
Temperature 
(°C) 
Time 
(days) 
Fungus 
Aspergillus 
niger 
ATCC 6275 
Malt extract 
agar 
25 ± 2 5-7 
Bacteria 
Staphylococcus 
aureus 
ATCC 6538P Nutrient 
agar 
30 ± 2 2 
Bacteria Escherichia coli ATCC 8739 30 ± 2 2 
Algae 
Scenedesmus 
vaculatus 
SAG 211-8b 
Kuhl 
solution 
20 ± 2 21 
Algae 
Stichococcus 
bacillaris 
SAG 379-1a 20 ± 2 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Failure phases and qualification of each formulation during the experimental 
campaign 
Formulation Failure phase 
M
o
n
o
co
m
p
o
n
en
t 
BXT/AB Physical properties 
BXT/11 Physical properties 
ACTICIDE MBP Antimicrobial properties (before aging process) 
BIOPOL D212 Releasing test 
VANTOCIL IB Releasing test 
VANQUISH 100 Physical properties 
DENSIL P Physical properties 
P24-81 Antimicrobial properties (before aging process) 
BC 98-56 Physical properties 
BXT Antimicrobial properties (after aging process) 
M
u
lt
ic
o
m
p
o
n
en
t BXT/12C Physical properties 
BXT/10P Physical properties 
BXT/1 Physical properties 
BXT/5 Antimicrobial properties (before aging process) 
PL-UV-H-2B None 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Mechanical properties of the monocomponent formulations failing first phase 
tests 
Formulation 
name 
Dosage 
(% 
odw) 
Flow 
(mm) 
Fresh 
density 
(kg/m
3
) 
Mechanical properties (MPa) 
Compressive 
strength 
Flexural 
strength 
1 d 28d 1d 28d 
DENSIL P 
0 154 2450 19.1 47.8 4.8 8.2 
0.2 154 2435 19.3 48.3 4.6 9.4 
0.5 155 2435 8.5 41.1 2.2 7.2 
1.0 155 2435 4.4 42.1 1.2 8.3 
2.0 159 2422 n.d. 34.2 n.d. 7.3 
BC 98-56 
0 150 2432 12.8 33.5 3.5 6.8 
0.3 135 2465 n.d. 36.6 n.d. 7.6 
VANQUISH 100 
0 155 2450 15.4 33.6 3.3 6.5 
0.002 152 2392 14.2 33.1 2.9 6.1 
0.013 152 2401 13.1 29.2 2.8 5.6 
0.025 153 2417 13.4 27.4 3.0 5.5 
0.037 156 2439 12.8 30.9 3.0 5.4 
0.050 150 2427 12.8 27.4 2.5 5.8 
BXT/11 
0 117 2389 15.5 35.1 3.2 5.6 
0.15 118 2005 5.3 16.0 2.1 3.3 
0.18 122 2004 7.2 21.4 2.5 5.2 
0.20 121 2122 6.9 20.9 2.7 5.3 
0.22 127 2174 9.6 24.3 2.4 5.8 
BXT/AB 
0 117 2389 15.5 35.1 3.2 5.6 
0.01 120 2420 15.1 29.9 2.6 5.4 
0.05 125 2395 14.8 34.3 2.8 5.4 
0.10 128 2467 13.0 31.8 2.3 5.0 
0.15 124 2397 11.9 29.8 2.1 4.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Mechanical properties of the multicomponent formulations 
Formulation 
name 
Dosage 
(% 
odw) 
Flow 
(mm) 
Fresh 
density 
(kg/m
3
) 
Mechanical properties (MPa) 
Compressive 
strength 
Flexural 
strength 
1 d 28d 1d 28d 
BXT/1 
0 157 2426 12.5 36.7 3.7 7.5 
0.4 150 2465 n.d. 34.0 n.d. 6.7 
0.45 153 2439 n.d. 31.2 n.d. 6.5 
0.5 149 2468 n.d. 34.3 n.d. 6.3 
BXT/5 
0 165 2343 15.8 42.3 4.8 8.7 
0.08 170 2337 14.9 40.5 4.3 8.1 
0.15 167 2381 15.1 40.0 3.8 8.4 
0.2 165 2330 14.5 39.0 3.5 7.9 
0.4 168 2327 14.0 39.0 3.3 7.7 
BXT/10P 
0 125 2473 19.1 35.0 4.8 7.2 
0.8 117 2266 10.3 30.6 2.8 6.1 
1 120 2200 8.2 29.0 2.5 6.0 
BXT/12C 
0 117 2389 12.8 33.5 3.5 6.8 
0.6 120 2420 8.1 28.4 2.8 5.6 
1 125 2395 6.2 22.7 2.3 4.4 
PL-UV-H-2B 
0 148 2523 14.3 37.1 4.0 9.4 
0.15 152 2501 12.7 36.9 3.5 8.6 
0.2 145 2479 11.3 35.7 2.8 8.2 
0.3 150 2484 14.0 34.9 3.2 8.5 
 
 
 
Figure 1. Flowchart of the experimental campaign 
Figure 2. Releasing curves of the active from concrete fabricated with monocomponent 
formulations: a) ACTICIDE MBP, b) BIOPOL D212, c) VANTOCIL IB, d) P24-81, 
and e) BXT 
Figure 3. Releasing curves of the active from concrete fabricated with PL-UV-H-2B 
formulation 
Figure 4. Effectiveness of concrete made with Acticide MBP formulation against 
different microorganisms 
Figure 5. Effectiveness of concrete made with P 24-81 formulation against different 
microorganisms 
Figure 6. Effectiveness of concrete made with BXT formulation against different 
microorganisms: a) before and b) after the accelerated aging process 
Figure 7. Effectiveness of concrete made with BXT/5 formulation against different 
microorganisms: a) before and b) after the accelerated aging process 
Figure 8. Effectiveness of concrete made with PL-UV-H-2B formulation against 
different microorganisms: a) before and b) after the accelerated aging process 
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